ArticleCytotechnology2009
Suppression of growth of highly-metastatic human breast cancer cells by norcantharidin and its mechanisms of action.
Article in Cytotechnology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 43 citations in OpenAlex.
- Mechanisms of norcantharidin against renal tubulointerstitial fibrosis.Pharmacological reports : PR · 2024Review
- Bioactive constituents of animal-derived traditional Chinese medicinal materials for breast cancer: opportunities and challenges.Journal of Zhejiang University. Science. B · 2022Review
- NCTD elicits proapoptotic and antiglycolytic effects on colorectal cancer cells via modulation of Fam46c expression and inhibition of ERK1/2 signaling.Molecular medicine reports · 2020Article
- Insight into norcantharidin, a small-molecule synthetic compound with potential multi-target anticancer activities.Chinese medicine · 2020Review
- Contribution of p38 MAPK Pathway to Norcantharidin-Induced Programmed Cell Death in Human Oral Squamous Cell Carcinoma.International journal of molecular sciences · 2019Article
- Norcantharidin Suppresses YD-15 Cell Invasion Through Inhibition of FAK/Paxillin and F-Actin Reorganization.Molecules (Basel, Switzerland) · 2019Article
- Formulation and evaluation of norcanthridin nanoemulsions against the Plutella xylostella (Lepidotera: Plutellidae).BMC biotechnology · 2019Article
- Effect of norcantharidin on the proliferation, apoptosis, and cell cycle of human mesangial cells.Renal failure · 2017Article
- FAM46C is critical for the anti-proliferation and pro-apoptotic effects of norcantharidin in hepatocellular carcinoma cells.Scientific reports · 2017Article
- Antimetastatic effects of norcantharidin on hepatocellular carcinoma cells by up-regulating FAM46C expression.American journal of translational research · 2017Article
- PP2A: The Wolf in Sheep's Clothing?Cancers · 2015Review
- Synthesis of novel lipophilic N-substituted norcantharimide derivatives and evaluation of their anticancer activities.Molecules (Basel, Switzerland) · 2014Article
- Norcantharidin inhibits renal interstitial fibrosis by blocking the tubular epithelial-mesenchymal transition.PloS one · 2013Article
- Norcantharidin induced DU145 cell apoptosis through ROS-mediated mitochondrial dysfunction and energy depletion.PloS one · 2013Article
- Norcantharidin, derivative of cantharidin, for cancer stem cells.Evidence-based complementary and alternative medicine : eCAM · 2013Review
- The Synthetic Compound Norcantharidin Induced Apoptosis in Mantle Cell Lymphoma In Vivo and In Vitro through the PI3K-Akt-NF- κ B Signaling Pathway.Evidence-based complementary and alternative medicine : eCAM · 2013Article
- Norcantharidin, a protective therapeutic agent in renal tubulointerstitial fibrosis.Molecular and cellular biochemistry · 2012Review
- Article
- Norcantharidin induces melanoma cell apoptosis through activation of TR3 dependent pathway.Cancer biology & therapy · 2011Article
- Inhibitory effects of norcantharidin against human lung cancer cell growth and migration.Cytotechnology · 2010Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effects of norcantharidin (NCTD) on the growth of highly-metastatic human breast cancer cells were investigated by in vitro and ex vivo assays. Our results indicated that norcantharidin inhibited the in vitro growth of human breast cancer MDA-MB-231 cell line in dose- and time-dependent manners after the cancer cells were treated with norcantharidin at the concentrations of 6, 30 and 60 mumol/L for 24, 48 and 72 h. Moreover, the sera from the NCTD-treated rabbits after intravenous injection of NCTD at 15 and 30 min significantly suppressed the growth of the cancer cells ex vivo. The analyses by Hoechst 33258 staining and flow cytometry showed that the typical apoptotic morphological changes appeared and cell cycles arrested at G2/M phase in MDA-MB-231 cells after the cells were treated for 48 h with NCTD. In addition, NCTD down-regulated the expressions of anti-apoptotic protein Bcl-2 and up-regulated the expressions of pro-apoptotic protein Bax, eventually leading to the reduction of Bcl-2/Bax ratio in MDA-MB-231 cells. Furthermore, NCTD at concentrations of 6, 30 and 60 mumol/L dose-dependently reduced the phosphorylation of Akt and NF-kappaB expression in the breast cancer cell line. Induction of apoptosis and cell cycle arrest as well as reduction of Bcl-2/Bax ratio by NCTD may be the important mechanisms of action of NCTD suppressing the growth of MDA-MB-231 cells, which are associated with inhibition of the Akt and NF-kappaB signaling. Our findings suggest that norcantharidin may have a wide therapeutic and/or adjuvant therapeutic application in the treatment of human breast cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.